CancerLivER: Biomarker Card

Biomarker Card: Comprehensive information about a biomarker


Biomarker ID 2268
Detailed information
CancerLivER ID2268
Biomarker LIMK1, CENPE, FZD2, ENO2, ITGA9, COPA, KIAA0660, GTF2H1, VPS41, RGS20, MATK, STOML1, BASP1, EPB42, ALDH3B2, MEL, CAT56, RAB3A, PSCD3, PLD2, ADCYAP1R1, ALDH3B1, RHD, CSF3R, KIAA0063, KIAA0296, LRP6, ENO3, CTRB1, YES1, IncytePD:1404153, GYS1, MDFI, GABRE, IncytePD:2685601, CD3Z, DTYMK, SPTBN2, IncyteP
Biomarker Name/Symbol (given in Publication)152 genes-signature (LIMK1, CENPE, FZD2, ENO2, ITGA9, COPA, KIAA0660, GTF2H1, VPS41, RGS20, MATK, STOML1, BASP1, EPB42, ALDH3B2, MEL, CAT56, RAB3A, PSCD3, PLD2, ADCYAP1R1, ALDH3B1, RHD, CSF3R, KIAA0063, KIAA0296, LRP6, ENO3, CTRB1, YES1, IncytePD:1404153, GYS1, MDFI, GABRE, IncytePD:2685601, CD3Z, DTYMK, SPTBN2, IncytePD:2509789, HSD3B1, GUCA2B, ACOX3, CHGB, STUB1, RHAG, PMAIP1, CD37, EPHB4, PITX2, KIAA0084, LPL, PYGB, MN7, AP1S1, ESTs, IDS, CLCN7, SLC20A2, HMMR, IncytePD:1681876, DGKI, KIAA0406, INPP5B, EFNA3, SELENBP1, KHK, KIAA0225, LILRA2, GCLC, MMP9, HCGII-7, FZD5, IncytePD:1570216, PDK1, HOXB13, MKI67, ASPH, CES1, NDP52, IL2RB, FEN1, IL12A, KCNN3, DTR, PLA2G6, RFC5, TNFSF7, CPSF5, NFRKB, SCNN1B, RAB28, IRF2, LTBP4, CGI-85, ABL2, CRSP8, GAB1, AKR1C4, TNFRSF5, RELB, KIAA0095, FLJ20366, ESTs, ESTs,, DDEF1, ESTs,, GRTH, FLJ22049, ESTs, FLJ20764, KIAA0978, ESTs, KIAA0185, HTPAP, KIAA0974, SKI, FLJ20015, SH3GLB1, Homo, UBN1, SRP46, RPS6KA4, RANBP9, NS1-BP, IncytePD:2895226, FLJ23188, ESTs, HTCD37, DBH, FLJ10008, Homo, Homo, FLJ21439, KIAA0615, DKFZp434A2417, Similar to bromodomain-containing, ESTs similar to CASPASE-4 precursor, ESTs, DKFZP564G092, FLJ21913, UBXD2, TAZ, ESTs, DKFZP434B044, FLJ12366, UCP2, FLJ14225, GALK1, ESTs, HBG1, ESTs, FLJ21065)
BiomoleculeRNAs
SubjectHuman
Degree of ValidityTo classify HCC patients with intra-hepatic metastasis and validated on independent dataset
Experimental ConditionMetastatic HCC v/s Primary HCC
Cancer typeHepatocellular carcinoma
RegulationUpregulated in PT than PN (with 3 fold change)
Level of significance p < 0.01
SourceTissue
PMID12640447
Type of BiomarkerDiagnostic
PathwayNA
CohortThe 107 paired samples, including primary HCC, metastatic HCC and corresponding adjacent non-tumor liver tissue, were derived from 40 predominantly male and hepatitis B-positive Chinese patients with an average age of 50; 7 human hepatoma-derived cell lines (HuH1, HuH4, HuH7, MHCC97, SMMC7721, SK-H
SensitivityNA
SpecificityNA
AccuracyNA
AUC85%
DiseaseMetastatic HCC v/s Primary HCC
Year of Publication2003
Clinical trialNO
Clinical trial (NCT Number)NA

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top